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Whether oral anticoagulants (OACs) should be prescribed for patients with atrial 
fibrillation (AF) having a CHA2DS2-VASc score of 1 for males or 2 for females has been 
debated for years. The 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS 
guideline for the management of patients with atrial fibrillation (AF) states that OACs may 
be reasonable for this AF population (class IIb recommendation).
1
 This recommendation is 
less strong compared to that of the 2016 AF guidelines of European Society of Cardiology 
(class IIa recommendation) and the 2018 CHEST guidelines.
2,3
 These discrepancies of 
different important guidelines could make this difficult issue even more complicated. 
Current recommendations of the international guidelines may perhaps be too simplified 
regarding this area, and a more delicate approach for these patients is required. After all, 
clinical factor-based stroke risk stratification schemes such as the CHA2DS2-VASc score are 
reductionist in design with the aim to aid clinical decision-making in a simple and practical 
manner; indeed, the CHA2DS2-VASc score does not include all possible risk factors 
associated with stroke in AF. Second, stroke risk is a dynamic process, and a patient’s risk 
profile changes over time. Third, different risk factor components were not equal regarding 
the risk of ischemic stroke in AF patients with a CHA2DS2-VASc score of 1 for males or 2 
for females. For example, age 65-74 years and diabetes mellitus were associated with a 
higher risk of ischemic stroke than other risk factors among AF patients with one single risk 
factor beyond sex.
4
 Besides, since “age” is an important driver of ischemic stroke, the age of 
patients also should be taken into consideration when making decisions about stroke 
prevention, but age is also a continuum of risk such that an AF patient who is age 65 is 
clearly at lower risk than someone at age 74. Indeed, when that patient turns age 75 and gains 
2 points on the CHA2DS2-VASc score, it does not mean that their risk is doubled.  
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The introduction of the non-vitamin K antagonist OACs (NOACs) have changed the 
landscape of stroke prevention. In our recent publication, we proposed that age thresholds for 
the use of NOACs were different for AF patients having different single risk factors beyond 
sex despite the same CHA2DS2-VASc score point (1 for males and 2 for females); that is, 
35 years for heart failure, 50 years for hypertension or diabetes, and 55 years for vascular 
diseases.
5
 We therefore suggest that “age” and “comorbidity” are two important factors 
which should be considered to be incorporated into the guideline recommendations for the 
use of OACs for patients with a CHA2DS2-VASc score of 1 for males or 2 for females 
(Figure 1), notwithstanding the fact that clinicians should recognize that risk stratification is 
designed with practicality in mind and that stroke risk is dynamic rather than static. 
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Figure legend: 
 
Figure 1. Different recommendations in important guidelines and the delicate approach about 
stroke prevention for AF patients with a CHA2DS2-VASc score of 1 (males) or 2 (females). 
ACC = American College of Cardiology; AF = atrial fibrillation; AHA = American Heart 
Association; ESC = European Society of Cardiology; NOACs = non-vitamin K antagonist 
oral anticoagulants 
 
